China Resources Double-Crane Pharmaceutical Co Ltd (600062) - Total Assets
Based on the latest financial reports, China Resources Double-Crane Pharmaceutical Co Ltd (600062) holds total assets worth CN¥17.01 Billion CNY (≈ $2.49 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore how much of China Resources Double-Crane Pharmaceuti's assets are long-term investments to see how much of total assets are deployed in long-term investments.
China Resources Double-Crane Pharmaceutical Co Ltd - Total Assets Trend (1994–2024)
This chart illustrates how China Resources Double-Crane Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. Check China Resources Double-Crane Pharmaceuti asset resilience ratio to evaluate the company's liquid asset resilience ratio.
China Resources Double-Crane Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
China Resources Double-Crane Pharmaceutical Co Ltd's total assets of CN¥17.01 Billion consist of 44.8% current assets and 55.2% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 17.1% |
| Accounts Receivable | CN¥2.78 Billion | 16.7% |
| Inventory | CN¥1.59 Billion | 9.6% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥2.47 Billion | 14.8% |
| Goodwill | CN¥878.49 Million | 5.3% |
Asset Composition Trend (1994–2024)
This chart illustrates how China Resources Double-Crane Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 600062 market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: China Resources Double-Crane Pharmaceutical Co Ltd's current assets represent 44.8% of total assets in 2024, a decrease from 58.1% in 1994.
- Cash Position: Cash and equivalents constituted 17.1% of total assets in 2024, up from 0.8% in 1994.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 19.0% of total assets, an increase from 0.0% in 1994.
- Asset Diversification: The largest asset category is accounts receivable at 16.7% of total assets.
China Resources Double-Crane Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of China Resources Double-Crane Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
|
China | CN¥68.33 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Ajanta Pharma Limited
NSE:AJANTPHARM
|
India | Rs56.72 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
|
Guizhou Bailing Group Pharmaceutical Co Ltd
SHE:002424
|
China | CN¥5.95 Billion |
China Resources Double-Crane Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.25 | 1.59 | 2.55 |
| Quick Ratio | 1.75 | 1.26 | 2.06 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥4.08 Billion | CN¥2.72 Billion | CN¥4.13 Billion |
China Resources Double-Crane Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between China Resources Double-Crane Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.68 |
| Latest Market Cap to Assets Ratio | 0.15 |
| Asset Growth Rate (YoY) | 8.1% |
| Total Assets | CN¥16.69 Billion |
| Market Capitalization | $2.56 Billion USD |
Valuation Analysis
Below Book Valuation: The market values China Resources Double-Crane Pharmaceutical Co Ltd's assets below their book value (0.15x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: China Resources Double-Crane Pharmaceutical Co Ltd's assets grew by 8.1% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for China Resources Double-Crane Pharmaceutical Co Ltd (1994–2024)
The table below shows the annual total assets of China Resources Double-Crane Pharmaceutical Co Ltd from 1994 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥16.69 Billion ≈ $2.44 Billion |
+8.13% |
| 2023-12-31 | CN¥15.43 Billion ≈ $2.26 Billion |
+6.55% |
| 2022-12-31 | CN¥14.48 Billion ≈ $2.12 Billion |
+5.90% |
| 2021-12-31 | CN¥13.68 Billion ≈ $2.00 Billion |
+10.14% |
| 2020-12-31 | CN¥12.42 Billion ≈ $1.82 Billion |
+10.11% |
| 2019-12-31 | CN¥11.28 Billion ≈ $1.65 Billion |
+9.42% |
| 2018-12-31 | CN¥10.31 Billion ≈ $1.51 Billion |
+9.20% |
| 2017-12-31 | CN¥9.44 Billion ≈ $1.38 Billion |
+14.52% |
| 2016-12-31 | CN¥8.24 Billion ≈ $1.21 Billion |
+6.16% |
| 2015-12-31 | CN¥7.76 Billion ≈ $1.14 Billion |
+17.28% |
| 2014-12-31 | CN¥6.62 Billion ≈ $968.61 Million |
+2.14% |
| 2013-12-31 | CN¥6.48 Billion ≈ $948.36 Million |
-0.41% |
| 2012-12-31 | CN¥6.51 Billion ≈ $952.29 Million |
+7.09% |
| 2011-12-31 | CN¥6.08 Billion ≈ $889.25 Million |
+16.74% |
| 2010-12-31 | CN¥5.21 Billion ≈ $761.73 Million |
+10.36% |
| 2009-12-31 | CN¥4.72 Billion ≈ $690.24 Million |
+10.49% |
| 2008-12-31 | CN¥4.27 Billion ≈ $624.69 Million |
+16.21% |
| 2007-12-31 | CN¥3.67 Billion ≈ $537.54 Million |
+12.71% |
| 2006-12-31 | CN¥3.26 Billion ≈ $476.94 Million |
-14.53% |
| 2005-12-31 | CN¥3.81 Billion ≈ $558.00 Million |
-5.27% |
| 2004-12-31 | CN¥4.03 Billion ≈ $589.02 Million |
-5.46% |
| 2003-12-31 | CN¥4.26 Billion ≈ $623.06 Million |
+17.74% |
| 2002-12-31 | CN¥3.62 Billion ≈ $529.20 Million |
+31.69% |
| 2001-12-31 | CN¥2.75 Billion ≈ $401.87 Million |
+85.04% |
| 2000-12-31 | CN¥1.48 Billion ≈ $217.18 Million |
+25.26% |
| 1999-12-31 | CN¥1.18 Billion ≈ $173.38 Million |
+59.89% |
| 1998-12-31 | CN¥741.02 Million ≈ $108.43 Million |
+28.94% |
| 1997-12-31 | CN¥574.69 Million ≈ $84.10 Million |
+272.44% |
| 1996-12-31 | CN¥154.30 Million ≈ $22.58 Million |
+16.64% |
| 1995-12-31 | CN¥132.29 Million ≈ $19.36 Million |
+0.73% |
| 1994-12-31 | CN¥131.33 Million ≈ $19.22 Million |
-- |
About China Resources Double-Crane Pharmaceutical Co Ltd
China Resources Double-Crane Pharmaceutical Co.,Ltd. operates as a pharmaceutical company in the People's Republic of China. The company offers pharmaceutical products for blood pressure, blood sugar, injection, lipid-lowering, pediatrics, nephrology, API, pharmaceutical, psychiatry/neurology, anticoagulation, oncology, women's health, anesthesia, and analgesia. The company was founded in 1939 an… Read more